Heart disease in patients with type 2 diabetes and previous myocardial infarction Circulatory System
Conditions
Interventions
This is a crossover study to characterise the cardiac effects of sitagliptin and empagliflozin on CMR imaging biomarkers and glycaemic status in patients with type 2 diabetes with a history of myocard
Sponsors
University of Leeds
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Type 2 diabetes mellitus 2. Metformin as single or dual therapy 3. Recent heart attack (48mmol/ml 5. 18-84 years old 6. Ability to provide informed consent
Exclusion criteria
Exclusion criteria: 1. Previous coronary artery bypass grafting (CABG) 2. Need for further revascularisation 3. Contra-indication to CMR scanning (some pacemakers, intraorbital debris, intraauricular implants, intracranial clips etc) 4. Contra-indication to Adenosine 5. Known allergy to contrast medium (gadolinium) 6. Renal dysfunction with eGFR< 60 7. Obesity where girth exceeds the scanner bore 8. Pregnancy or breastfeeding 9. Inability to lie flat for CMR scan
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myocardial perfusion reserve in remote myocardium, measured by cardiac MRI at baseline, 12 and 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Myocardial perfusion reserve in infarcted territory 2. Extracellular volume fraction 3. Capillary permeability 4. Relationship between glycaemic markers and LV perfusion parameters 5. Aortic distensibility Secondary outcome measures will be measured by cardiac MRI at baseline and at weeks 12 and 24. Secondary outcome measure 4 will also be measured at approximately 2 weeks before baseline and at weeks 10 and 22. | — |
Countries
England, United Kingdom
Outcome results
None listed